ClinOleic

An olive oil-based lipid emulsion that is associated with fewer infections than soybean oil and may preserve immune function.1-4

See indications Contact Us
ClinOleic product image

Lipids are an integral part of parenteral nutrition (PN), but some lipid emulsions, such as 100% soybean oil, may modulate patient immune response and increase the risk of complications.3,5 Through 20 years of experience, ClinOleic maintains the lowest soybean oil content of any soy-containing composite lipid emulsion.6-11  ClinOleic also contains 80% olive oil, which has been associated with fewer infections and may preserve immune function.1-4 

See full prescribing information

Doctor and a nurse are talking to a patient in a hospital bed

Critically ill patients may be immunocompromised and vulnerable to complications

Major trauma often results in massive impairment of immunologic activity.12 Meanwhile, excessive use of 100% soybean oil-based lipids may have pro-inflammatory effects and potentially may put patients at risk for intestinal failure associated liver disease (IFALD) which can be life-threatening.13 Still, lipids are an integral part of PN as they are a dense source of calories and provide essential fatty acids.14 When determining which lipid to use, it may be advantageous to prescribe an alternative lipid like ClinOleic, which provides the required energy and essential fatty acids and minimizes the concern with providing more pro-inflammatory Omega-6 fatty acids associated with lipids based solely on soybean oil.15

Vein structure in human body

Olive oil-based PN may preserve immune function1-4

Olive oil is rich in long chain Omega-9 monounsaturated fatty acids (MUFAs) with fewer polyunsaturated fatty acids (PUFAs) than the fatty acids contained in soybean and fish oil.16 Olive oil-based lipid emulsions may avoid the impairment of the immune response associated with omega-6 PUFAs and may achieve an immunologically neutral effect.15

Graph showing total infections, no. of patients infected, lungs infections & no. of nonspecified infections

A three-chamber bag containing ClinOleic has been associated with fewer infections than a compounded formulation containing 100% soybean oil

In a large, randomized, prospective, open-label multicenter PN study of 458 patients, parenteral nutrition regimen containing olive oil-based lipid emulsion was associated with fewer infections, provided effective nutrition, and was well tolerated.17

Abstract image of oil and olives

Aligned with international guidelines

ASPEN guidelines recommend to withhold or limit soybean oil-based lipid emulsions during the first week following the initiation of PN.18 Additionally, ESPEN guidelines recommend that lipids based solely on soybean oil be avoided.14 ClinOleic has the lowest soybean oil content of any soy-containing composite lipid product on the market, enabling the delivery of essential fatty acids while minimizing the unwanted effects of soybean oil.6-11,15

Learn more about Clinical Nutrition

Going through patient file

Visit the Clinical Nutrition Resource Library to access additional resources

Related Products

FACHKURZINFORMATION

Clinoleic 20 % - Emulsion zur Infusion

ATC - Code: B05BA02

QUALITATIVE UND QUANTITATIVE ZUSAMMENSETZUNG: 100 ml enthalten: Gereinigtes Olivenöl und gereinigtes Sojaöl* 20,00 g entsprechend einem Gehalt an essentiellen Fettsäuren von 4,00 g * Mischung aus gereinigtem Olivenöl (ca. 80 %) und gereinigtem Sojaöl (ca. 20%) Energiegehalt 2000 kcal/l (8,36 MJ/l) Fettgehalt (Oliven- und Sojaöl) 200 g/l Osmolarität 270 mOsm/l pH-Wert 6-8 Dichte 0,986 Phospholipide, entsprechend 47 mg oder 1,5 mmol Phosphor pro 100 ml Liste der sonstigen Bestandteile: Phospholipide aus Eiern, Glycerol, Natriumoleat, Natriumhydroxid, Wasser für Injektionszwecke

ANWENDUNGSGEBIETE:
Indiziert zur Fettzufuhr für Patienten, die parenteral ernährt werden müssen, wenn eine orale oder enterale Ernährung unmöglich, unzureichend oder kontraindiziert ist.

GEGENANZEIGEN:
Clinoleic 20 % ist in folgenden Situationen kontraindiziert: Überempfindlichkeit gegen Ei-, Soja- oder Erdnussprotein oder gegen einen der Wirkstoffe oder sonstigen Bestandteile, schwere Dyslipidämie und nicht korrigierte Stoffwechselstörungen wie Laktatazidose und entgleister Diabetes.

INHABER DER ZULASSUNG:
Baxter Healthcare GmbH, Stella-Klein-Löw-Weg 15, 1020 Wien

STAND DER INFORMATION

VERSCHREIBUNGSPFLICHT/APOTHEKENPFLICHT: Rezept- und apothekenpflichtig.

Weitere Angaben zu „Besondere Warnhinweise und Vorsichtsmaßnahmen für die Anwendung“, „Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen“, „Fertilität, Schwangerschaft und Stillzeit“ und „Nebenwirkungen“ sind der veröffentlichten Fachinformation zu entnehmen.